Claims
- 1. A compound of Formula I or a pharmaceutically acceptable salt thereof
- 2. The compound of claim 1 having the Formula Ia or a pharmaceutically acceptable salt thereof
- 3. The compound of claim 1 selected from the group consisting of:
(R)-N-[2-hydroxy-1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-propionamide; (R)-3-(2-fluoro-phenyl)-N-[2-hydroxy-1-(3-morpholin-4-yl-phenyl)-ethyl]-acrylamide; (R)-3-(3-fluoro-phenyl)-N-[2-hydroxy-1-(3-morpholin-4-yl-phenyl)-ethyl]-acrylamide; (R)-3-(2,4-difluoro-phenyl)-N-[2-hydroxy-1-(3-morpholin-4-yl-phenyl)-ethyl]-acrylamide; (R)-N-[1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl]-3-(2-fluorophenyl)-acrylamide; (R)-N-[1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl]-3-(3-fluorophenyl)-acrylamide; (R)-N-[1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl]-3-(4-fluorophenyl)-acrylamide; (R)-3-(2,4-difluoro-phenyl)-N-[1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl]-acrylamide; (R)-3-(3-fluoro-phenyl)-N-(2-hydroxy-1-naphthalen-2-yl-ethyl)-acrylamide; (R)-3-(4-fluoro-phenyl)-N-(2-hydroxy-1-naphthalen-2-yl-ethyl)-acrylamide; (R)-3-(2,4-difluoro-phenyl)-N-(2-hydroxy-1-naphthalen-2-yl-ethyl)-acrylamide; (R)-3-(3,4-difluoro-phenyl)-N-(2-hydroxy-1-naphthalen-2-yl-ethyl)-acrylamide; (R)-4-fluoro-N-(2-hydroxy-1-naphthalen-2-yl-ethyl)-benzamide; (R)-2,3-difluoro-N-(2-hydroxy-1-naphthalen-2-yl-ethyl)-benzamide; (R)-2,4-difluoro-N-(2-hydroxy-1-naphthalen-2-yl-ethyl)-benzamide; (R)-3,4-difluoro-N-(2-hydroxy-1-naphthalen-2-yl-ethyl)-benzamide; (R)-2-(2,4-difluoro-phenyl)-N-(2-hydroxy-1-naphthalen-2-yl-ethyl)-acetamide; (R)-3-(2-fluoro-phenyl)-N-(2-hydroxy-1-naphthalen-2-yl-ethyl)-propionamide; (R)-3-(3-fluoro-phenyl)-N-(2-hydroxy-1-naphthalen-2-yl-ethyl)-propionamide; (R)-3-(4-fluoro-phenyl)-N-(2-hydroxy-1-naphthalen-2-yl-ethyl)-propionamide; (R)-3-(2,4-difluoro-phenyl)-N-(2-hydroxy-1-naphthalen-2-yl-ethyl)-propionamide; (R)-3-(2-fluoro-phenyl)-N-[2-hydroxy-1-(7-methoxy-naphthalen-2-yl)-ethyl]-acrylamide; (R)-3-(3-fluoro-phenyl)-N-[2-hydroxy-1-(7-methoxy-naphthalen-2-yl)-ethyl]-acrylamide; (R)-3-(4-fluoro-phenyl)-N-[2-hydroxy-1-(7-methoxy-naphthalen-2-yl)-ethyl]-acrylamide; (R)-3-(2,4-difluoro-phenyl)-N-[2-hydroxy-1-(7-methoxy-naphthalen-2-yl)-ethyl]-acrylamide; (1R,2S)-N-(2,3-dihydroxy-1-naphthalen-2-yl-propyl)-3-(2-fluoro-phenyl)-acrylamide; (1R,2S)-3-(2,4-difluoro-phenyl)-N-(2,3-dihydroxy-1-naphthalen-2-yl-propyl)-acrylamide; (1R,2S)-3-(3,4-difluoro-phenyl)-N-(2,3-dihydroxy-1-naphthalen-2-yl-propyl)-acrylamide; and (1R,2S)-3-(3,5-difluoro-phenyl)-N-(2,3-dihydroxy-1-naphthalen-2-yl-propyl)-acrylamide; or a pharmaceutically acceptable salt thereof.
- 4. A pharmaceutical composition for the treatment of disorders responsive to opening of KCNQ potassium channels comprising a therapeutically effective amount of the compound of claim 1 in association with a pharmaceutically acceptable carrier, adjuvant or diluent.
- 5. A method for the treatment of disorders responsive to opening of the KCNQ potassium channels in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of the compound of claim 1.
- 6. The method of claims 5 wherein said disorders are acute and chronic pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders.
- 7 The method of claim 6 wherein said disorder is migraine.
- 8. The method of claim 6 wherein said disorder is neuropathic pain.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This is a non-provisional application which claims the benefit of U.S. Provisional Application No. 60/428,338 filed Nov. 22, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60428338 |
Nov 2002 |
US |